DigmBio is a biotech company headquartered in Korea, dedicated to developing innovative pharmaceuticals targeting critical unmet medical needs. Our management team has decades of collective experience in new drug development and global clinical trials, particularly in the realm of small molecule therapeutics. Our pipeline encompasses therapies for oncology, Alzheimer's disease, and other CNS diseases including Parkinson's disease. 

DM5167, a second-generation PARP1 selective inhibitor, is currently undergoing review by the Institutional Review Board (IRB) for phase 1 clinical trials in Korea. Preclinical data highlight significant advancements of DM5167 over first-generation PARP inhibitors, in efficacy, toxicity profiles, and blood-brain barrier (BBB) penetration with the brain-to-plasma concentration ratio (Kp,brain) of 0.89. DM5167 targets cancers with BRCA mutation and/or homologous recombination deficiency (HRD), as well as metastatic brain tumors, making it an ideal candidate for combination therapies. 

Our Alzheimer's disease candidate, DM3159, targets neuroprotection and neurogenesis as a disease-modifying therapy, diverging from traditional approaches focused on beta-amyloid or Tau protein for symptomatic relief. Early-stage preclinical data for DM3159 indicates differentiated efficacy, toxicity, and BBB penetration. Recognized by the Korean government, DigmBio has received grants to advance not only Alzheimer's disease treatments but also those for CNS disorders including Parkinson's disease.

Digmbio Inc.

Org chart

Teams

Offices